| Title: | Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma : A Multicenter, Retrospective Cohort Study (HGCSG2101) |
| Authors: | Harada, Kazuaki Browse this author |
| Yamamura, Takahiro Browse this author |
| Muto, Osamu Browse this author |
| Nakamura, Michio Browse this author |
| Sogabe, Susumu Browse this author |
| Sawada, Kentaro Browse this author |
| Nakano, Shintaro Browse this author |
| Yagisawa, Masataka Browse this author |
| Muranaka, Tetsuhito Browse this author |
| Dazai, Masayoshi Browse this author |
| Tateyama, Miki Browse this author |
| Kobayashi, Yoshimitsu Browse this author |
| Kato, Sosuke Browse this author |
| Hatanaka, Kazuteru Browse this author |
| Kawamoto, Yasuyuki Browse this author |
| Yuki, Satoshi Browse this author |
| Sakata, Yuh Browse this author |
| Sakamoto, Naoya Browse this author |
| Komatsu, Yoshito Browse this author →KAKEN DB |
| Keywords: | pancreatic cancer |
| nanoliposomal irinotecan |
| nal-IRI |
| irinotecan |
| Issue Date: | Feb-2023 |
| Publisher: | MDPI |
| Journal Title: | Journal of clinical medicine |
| Volume: | 12 |
| Issue: | 4 |
| Start Page: | 1596 |
| Publisher DOI: | 10.3390/jcm12041596 |
| Abstract: | The effects of UGT1A1 gene polymorphisms or prior irinotecan treatment on treatment outcomes of nanoliposomal-irinotecan plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with unresectable pancreatic ductal adenocarcinoma (PDAC) are not established. This multicenter, retrospective cohort study compared treatment outcomes in patients with UGT1A1*1/*1 and those with UGT1A1*1/*6 or *1/*28 genotypes. We also analyzed the impact of prior irinotecan treatment on survival outcomes in 54 patients treated with nal-IRI+5-FU/LV. Comparable effectiveness was found regardless of the UGT1A1 genotypes. While no significant differences were found, grade >= 3 neutropenia and febrile neutropenia were more frequent in patients with UGT1A1*1/*6 or *1/*28 than in those with UGT1A1*1/*1 genotypes (grade >= 3 neutropenia, 50.0% vs. 30.8%, p = 0.24; febrile neutropenia, 9.1% vs. 0.0%, p = 0.20, respectively). No significant difference in progression-free survival (PFS) and overall survival (OS) was observed between irinotecan-naive-patients and other patients. However, irinotecan-resistant patients showed significantly shorter PFS (hazard ratio (HR) 2.83, p = 0.017) and OS (HR 2.58, p = 0.033) than other patients. Our study indicated that patients with UGT1A1*1/*6 or *1/*28 may be prone to neutropenia, though further study is needed. The survival benefit of nal-IRI+5-FU/LV could be maintained in patients without disease progression after irinotecan therapy. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/89269 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
